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Two different sites on vitamin K-dependent γ-glutamyl car-
boxylase (VKC) are involved in enzyme–substrate interaction:
the propeptide-binding site required for high-affinity substrate
binding and the active site for glutamate carboxylation. Synthetic
descarboxy osteocalcin (d-OC) is a low-K
m
substrate for the
VKC, but unique since it possesses a high-affinity recognition site
for the VKC, distinct from the propeptide which is essential as a
binding site for VKC. However, the exact location and com-
position of this VKC-recognition domain on d-OC has remained
unclear until now. Using a stereospecific substrate analogue
[t-butyloxycarbonyl-(2S,4S)-4-methylglutamic acid-Glu-Val
(S-MeTPT)] we demonstrate in this paper that the high affinity of
d-OC for VKC cannot be explained by a direct interaction with
either the active site or with the propeptide-binding site on VKC.
INTRODUCTION
All known proteins containing γ-carboxyglutamate (Gla) resi-
dues are synthesized in a precursor form [1] in which a propeptide
sequence preceding the Gla domain serves as a high-affinity
recognition site for vitamin K-dependent γ-glutamyl carboxylase
(VKC) [2–4]. This concept implies that at least two separate sites
on VKC must be involved in substrate interaction: a docking
site for substrate recognition and binding, and an active site at
which Glu residues are converted into Gla residues [2]. Small
synthetic Glu-containing peptides lacking this propeptide se-
quence (the pentapeptide Phe-Leu-Glu-Glu-Leu) do not bind to
the docking site but diffuse directly into the active site and are
poor substrates with K
m
values in the millimolar range [5,6].
Osteocalcin (OC) is a relatively small protein (5.8 kDa) which
has been shown, after thermal decarboxylation, to could serve as
a substrate for VKC in the absence of a covalently attached
propeptide [1,7]. Experiments of Benton et al. [8] indicated that
heat-decarboxylated bovine OC is a low-K
m
substrate for VKC
in the presence of the propeptide sequence of human Factor X
[8]. Although the precursor molecule of OC is covalently attached
to its propeptide, it has been demonstrated that the affinity of
this propeptide for VKC is low and that it probably does not
contribute significantly to the enzyme–substrate interaction [8,9].
Stanley et al. [10] suggested that this might be explained by the
presence of a glycine residue at position ®10 and a valine at
position ®6 of the propeptide, instead of the respective highly
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It is shown using various synthetic peptides derived from d-OC
that there are two domains on d-OC necessary for recognition:
one located between residues 1 and 12 and a second between
residues 26 and 39, i.e. at the C-terminal side of the γ-carboxy-
glutamate (Gla) domain. Both internal sequences contribute
substantially to the efficiency of carboxylation. On the basis
of these data we postulate the presence of a second high-affinity
substrate-binding site on VKC capable of specifically binding
d-OC, which is the first vitamin K-dependent substrate of which
the VKC binding domain is interrupted by the Gla domain.
Key words: bone, γ-carboxyglutamate, phylloquinone, post-
translational processing.
conserved alanine and leucine residues in these positions in all
other propeptides of the vitamin K-dependent proteins. Within
the OC molecule no homology with a propeptide structure can
be found, in contrast to matrix Gla protein (MGP), which is the
only vitamin K-dependent protein that has developed a propep-
tide within its mature amino acid sequence [11]. Stanley et al. [9]
postulated that for OC essential elements other than the propep-
tide appear to be involved in substrate recognition [9]. The
question remains about which structural determinants of full-
length synthetic descarboxy osteocalcin (d-OC"–%*) contribute to
its high affinity for VKC.
In previous experiments we showed that d-OC does not bind
to the propeptide-binding site on VKC and that it must have an
internal recognition sequence that binds to carboxylase at a site
different from the propeptide-recognition site. Based on these
observations we have postulated a second substrate-docking site
on VKC [12]. A possible explanation is that the active site itself
functions as the high-affinity docking site for d-OC. To investigate
this hypothesis, the kinetic characteristics of d-OC"–%* were com-
pared with a tripeptide substrate and a pro-containing substrate
in the absence and presence of the methylated tripeptide Boc-
(2S,4S)-4-methylglutamic acid-Glu-Val (S-MeTPT; where Boc is
t-butyloxycarbonyl), a stereo-specific substrate analogue, acting
as an active-site inhibitor [13]. To further investigate which
domain within the d-OC"–%* protein is responsible for the high-
affinity binding to VKC, the peptides d-OC"–#&, d-OC$–#&, d-
OC&–#&, d-OC(–#&, d-OC"!–#&, d-OC"$–#&, d-OC"&–#&, d-OC"&–$! and
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d-OC"&–$* were synthesized and their K
m
values were compared
with those of d-OC"–%* and two recombinant glutathione S-
transferase (GST)-fused recombinant human d-OC molecules,
GST-rhOC"–%* and GST-rhOC"–$*, containing truncated recom-




All chemicals were of analytical grade or better. Vitamin K
"
(Konakion2, mixed micelles) was purchased from Hoffmann-La
Roche (Basel, Switzerland), NaH"%CO
$
with a specific activity of
50 mCi}mmol was from NEN (Boston, MA, U.S.A.) and
CHAPS was from Sigma (St. Louis, MO, U.S.A.).
Preparation of microsomes from Trichoplusia ni High-Five insect
cells
Expression of r-carboxylase in T. ni High-Five insect cells, the
preparation of microsomes and the purification of r-carboxylase
using HPC4 antibody resin was performed as described by
Houben et al. [12].
Peptides and proteins
d-OC was synthesized according to Wuyts et al. [14] and was a
kindly given by Dr Rob H.M. Ebberink (Perkin-Elmer Nether-
lands, Nieuwerkerk aan de IJssel, The Netherlands) and Dr
Paul Proost (The Rega Institute, Department of Molecular
Immunology, Catholic University of Leuven, Leuven, Belgium).
The tripeptide Boc-Glu-Glu-Leu-methyl ester (bEELOMe) was
from Bachem (Bubendorf, Switzerland). Boc-(2S,4S)-4-methyl-
glutamic acid was synthesized according to Righini-Tapie and
Azerad [15] and incorporated into S-MeTPT via a sequential
method using selectively protected γ-benzyl, α-N-hydroxysuc-
cinimide esters [15,16]. ProIX-59 Q}S, a 59 amino acid peptide
containing the human Factor IX propeptide and the first 41
residues of Factor IX Gla domain (sequence ®18 to 41), with an
Arg-to-Gln mutation at the ®4 position and an Arg-to-Ser
mutation at position ®1, was produced and purified as described
previously [4]. The propeptides (sequence ®18 to ®1) of the
human precursor molecules of OC (ProOC) and blood coagula-
tion Factor IX (ProFIX) were synthesized by Pepscan Systems
(Lelystad, The Netherlands).
GST-rhOC"–%* and GST-rhOC"–$* were produced and purified
according to Ka$ ko$ nen et al. [17] and Hellman et al. [18]
respectively. d-OC"–%* was synthesized by Dr Paul Proost, ac-
cording to Wuyts et al. [14].
The peptides d-OC"–#&, d-OC$–#&, d-OC&–#&, d-OC(–#&, d-
OC"!–#&, d-OC"$–#&, d-OC"&–#&, d-OC"&–$! and d-OC"&–$* were
synthesized automatically on an Applied Biosystems 433A Pep-
tide Synthesizer (Applied Biosystems, Foster City, CA, U.S.A.)
using the FastMoc2 protocol [19] on 0.25 mmol scale. Peptide
syntheses were carried out on TentaGel2 S RAM resin (1 g,
0.24 mmol) functionalized with a 4-[(2«,4«-dimethoxyphenyl)
amino methyl]phenoxyacetamido moiety (Rink amide linker
[20] ; Rapp Polymere, Tu$ bingen, Germany) to obtain C-terminal
amides. Fluoren-9-ylmethoxycarbonyl (Fmoc)-protected amino
acids with the following side-chain protection were used: Boc
for Trp [21], t-butyl for Tyr, t-butyl ester for Asp and Glu, trityl for
Gln and Cys, and 2,2,4,6,7-pentamethyl-dihydrobenzofuran-5-
sulphonyl (Pbf) for Arg [22]. Coupling of Fmoc amino acids
(1 mmol, 4 equiv.) was performed with 2-(1H-benzotriazol-1-yl)-
1,1,3,3-tetramethyluronium tetrafluoroborate}N-hydroxybenzo-
triazole (HBTU}HOBt) [23] in the presence of 2 mmol of N,
Table 1 Comparison of obtained and calculated molecular masses of d-OC
fragments
Ac, acetyl.
OC Peptide amino acid composition
Molecular mass [(M­H)+ ; Da]
Obtained Calculated
d-OC1–25 Ac-YLYQWLGAPVPYPDPLEPRREVCEL-NH2 3046.2 3046.53
d-OC3–25 Ac-YQWLGAPVPYPDPLEPRREVCEL-NH2 2769.6 2770.19
d-OC5–25 Ac-WLGAPVPYPDPLEPRREVCEL-NH2 2478.35 2478.88
d-OC7–25 Ac-GAPVPYPDPLEPRREVCEL-NH2 2179.45 2179.51
d-OC10–25 Ac-VPYPDPLEPRREVCEL-NH2 1953.3 1952.99
d-OC13–25 Ac-PDPLEPRREVCEL-NH2 1593.3 1593.81
d-OC15–25 Ac-PLEPRREVCEL-NH2 1382.03 1381.73
d-OC15–30 Ac-PLEPRREVCELNPDCD-NH2 1925.95 1925.88
d-OC15–39 Ac-PLEPRREVCELNPDCDELADHIGFQ-NH2 2937.13 2936.37
N-di-isopropylethylamine (DIPEA) in N-methylpyrrolidinone
(NMP) for 45 min. Fmoc removal was carried out with 25%
piperidine in NMP for 10 min. The peptides were cleaved from
the resin and deprotected by treatment with trifluoroacetic acid
(TFA)}water}1,2-ethanedithiol (76:4:20, by vol.) at room tem-
perature for 3 h [24]. The peptides were precipitated with diethyl
ether}hexane (1:1, v}v) at ®20 °C. The precipitates were decant-
ed and subsequently washed with cold diethyl ether}hexane (1:
1, v}v; three times) and finally lyophilized from t-butanol}water
(1:1, v}v).
Peptide purification
Preparative HPLC was performed on a Gilson HPLC
workstation (Middleton, WI, U.S.A.) using Adsorbosphere XL
C
")
with 10 µm particle size and 300 AI pore size (length, 250 mm ;
internal diameter, 22 mm) (Alltech Corp., Deerfield, IL, U.S.A.),
consisting of two 306 pumps, a 811C dynamic mixer, a 806
manometric module, a 119 UV}visible detector, a 402 syringe
pump and a 233XL online column switching autoinjector (frac-
tion collector). The HPLC runs were controlled by Gilson
Unipoint4 System Software (version 1.65). Crude lyophilized
peptides (30–100 mg) were dissolved in 0.1% TFA in water and
loaded on to the HPLC column. The peptides were eluted at a
flow rate of 11.5 ml}min using a linear gradient of buffer B
(0–100% in 60 min), where buffer A is 0.1% TFA in water and
buffer B is 0.085% TFA in acetonitrile}water (95:5, v}v). After
purification the peptides were lyophilized from demineralized
water and stored at ®20 °C prior to biological testing.
Peptide characterization
Peptide purity was analysed by analytical HPLC on an Adsorbo-
sphere XL C
")
[5 µm particle size, 300 AI pore size (length,
250 mm; internal diameter, 4.6 mm)] at a flow rate of 1 ml}min
using a linear gradient of buffer B (0–100% in 30 min) from
100% buffer A (see above for buffer compositions). Purity was
determined to be 95% or higher. The peptides were characterized
by electrospray ionization MS on a Micromass Platform II
(Micromass U.K., Altrincham, Cheshire, U.K.) single quadru-
pole bench-top mass spectrometer operating in positive-ioniza-
tion mode. Instrumental control, data acquisition and data
processingwere carried out using theMassLynx software package
(version 2.3). The observed average m}z value was compared
with the calculated (M­H)+ average mass. An overview of the
mass comparison is given in Table 1.
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Carboxylase assay
Standard reaction mixtures (125 µl) contained 40 nM purified
recombinant carboxylase, 25 mM Tris}HCl, pH 7.4, 150 mM
NaCl, 0.28% CHAPS, 0.12% phosphatidylcholine, 5 µCi
of NaH"%CO
$
, 222 µM vitamin K hydroquinone and 6 mM
dithiothreitol. Exogenous substrates were added as indicated.
The mixture was incubated at 20 °C for 30 min in sealed tubes.
Kinetic analysis was performed on equal volumes removed from
the incubation mixture at t¯ 0, t¯ 15 and t¯30 min. Inhibition
experiments were done under the same reaction conditions and
incubation times as above. All reactions were stopped by adding
0.8 ml of 5% trichloroacetic acid to 100 µl of reaction mixture
and unbound "%CO
#
was removed by boiling for 3 min. Total
incorporation was determined using a Wallac 1414 WinSpectral2
liquid scintillation counter (EG&G Wallac, Turku, Finland).
Data are expressed as pmol of "%CO
#
incorporated}min. Kinetic
parameters were determined by fitting to the Michaelis–Menten
equation by non-linear regression [25].
RESULTS
Propeptide-binding-site inhibition
The importance of the propeptide sequence in substrate rec-
ognition was investigated by testing the effect of free ProFIX on
the carboxylation of recombinant ProIX-59Q}S.Aswas reported
Figure 1 Lineweaver–Burk plots of substrate carboxylation
Upper left panel : inhibition of ProIX-59 Q/S by increasing amounts of free ProFIX. ProFIX concentrations : *, 0 µM; D, 2 µM; +, 5 µM; E, 10 µM; ^, 20 µM. Upper right panel : inhibition
of bEELOMe by increasing concentrations of S-MeTPT. S-MeTPT concentrations : *, 0 µM; D, 100 µM; +, 200 µM; E, 400 µM. Lower left panel : inhibition of ProIX-59 Q/S by increasing
amounts of S-MeTPT. Concentrations were as for the upper right panel. Lower right panel : inhibition of d-OC by increasing amounts of S-MeTPT. Concentrations were as for the upper right panel.
Incubations took place at 20 °C for 30 min. All values are means from three independent measurements.
previously, ProIX-59 Q}S has a high affinity for VKC, which
makes it an efficient substrate for in itro vitamin K-dependent γ-
carboxylation [4]. As shown in Figure 1 (upper left panel),
ProIX-59 Q}S carboxylation is inhibited competitively by ProFIX
with a K
i
(app) value of 1.97³0.19 µM, which is consistent with
binding of substrate and inhibitor at the same site on VKC.
These data also suggest an initial interaction of the propeptide
sequence with the carboxylase propeptide-binding site rather
than with the active site.
Active-site inhibition
The kinetic characteristics of active-site inhibition by S-MeTPT
were assessed using the homologous tripeptide substrate
bEELOMe. This small substrate lacks a propeptide sequence
and therefore has a K
m
value in the millimolar range. S-MeTPT
is known to be an effective active-site inhibitor and, as shown in
Figure 1 (upper right panel), the carboxylation of bEELOMe is
inhibited competitively with a K
i
(app) of 289³35 µM. These
data illustrate that both inhibitor and substrate act directly on
the active site of VKC. In contrast, the inhibition of the ProIX-
59 Q}S carboxylation by S-MeTPT was found to be non-com-
petitive (Figure 1, lower left panel) with a K
i
(app) of 493³66 µM,
as was the inhibition of d-OC carboxylation by S-MeTPT
(Figure 1, lower right panel) which was found to be inhibited
with a K
i
(app) value of 491³30 µM (Table 2). The non-competitive
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Table 2 Kinetic parameters for carboxylation of bEELOMe, ProIX-59 Q/S and d-OC in the presence of S-MeTPT (a) or ProFIX (b)
Reactions were performed as detailed in the Materials and methods section using four concentrations of each substrate. Values are means³S.D. obtained from at least three independent







®S-MeTPT ­S-MeTPT ®S-MeTPT ­S-MeTPT
bEELOMe 1.2³0.3 mM 4.8³0.8 mM 289³35 µM 20.4³1.05 21.1³1.22
ProIX-59 Q/S 0.13³0.09 µM 0.19³0.08 µM 493³66 µM 3.3³0.15 1.9³0.19








®ProFIX ­ProFIX ®ProFIX ­ProFIX
ProIX-59 Q/S 0.13³0.09 µM 1.43³0.1 µM 1.97³0.19 µM 3.3³0.15 3.2³0.11
Table 3 Amino acid sequence overview of the d-OC peptides and proteins in combination with their kinetic parameters
Values are means³S.D. obtained from at least three independent determinations. Bold letters are Glu residues that become carboxylated. Units for Vmax are pmol of
14CO2 incorporated/min.
Position : 1 5 10 15 20 25 30 35 40 45 49 Km(µM) Vmax
d-OC1-49 YLYQWLGAPVPYPDPLEPRREVCELNPDCDELADHIGFQEAYRRFYGPV 3.14³0.23 23.0³1.41
GST-rhOC1-49 GST- YLYQWLGAPVPYPDPLEPRREVCELNPDCDELADHIGFQEAYRRFYGPV 3.00³0.47 21.1³1.19
GST-rhOC1-39 GST- YLYQWLGAPVPYPDPLEPRREVCELNPDCDELADHIGFQ 3.08³0.59 22.3³1.33
d-OC1-25 YLYQWLGAPVPYPDPLEPRREVCEL 29³8.90 15.8³1.17
d-OC3-25 YQWLGAPVPYPDPLEPRREVCEL 114³25 14.6³1.20
d-OC5-25 WLGAPVPYPDPLEPRREVCEL 125³21 14.5³1.11
d-OC7-25 GAPVPYPDPLEPRREVCEL 568³45 11.6³0.89
d-OC10-25 VPYPDPLEPRREVCEL 767³53 9.3³0.71
d-OC13-25 PDPLEPRREVCEL 10000³2250 41.8³3.11
d-OC15-25 PLEPRREVCEL 8200³1220 37.0³1.82
d-OC15-30 PLEPRREVCELNPDCD 2900³840 35.3³1.64
d-OC15-39 PLEPRREVCELNPDCDELADHIGFQ 102³12 12.8³1.23
nature of the active-site inhibition is consistent with a critical role
for the propeptide-binding site, rather than for the active site
during the formation of the enzyme–substrate complex. The
various kinetic characteristics are summarized in Table 2 and
show that S-MeTPT does not affect the K
m
(app) for ProIX-59
Q}S and d-OC but rather induces an increase in the K
m
(app) for
bEELOMe, which is in the millimolar range.
High-affinity binding site
In a purified recombinant human γ-glutamyl carboxylase system




values of the various d-OC
peptides. As can be seen in Table 3, subsequent N-terminal
deletion of amino acids from the d-OC"–#& peptide results in an
increase in the K
m
values of these peptides. On the other hand, C-
terminal elongation of the Gla domain results in a decrease of K
m
values. Both GST-rhOC"–%* and the deletion mutant GST-





values in Table 3.
DISCUSSION
The propeptide sequences which can be found in all precursors of
Gla-containing proteins show substantial sequence similarity;
notably the amino acid residues at ®16, ®10, ®6, ®4 and ®1
are highly conserved. OC, however, is the only known Gla
protein of which the propeptide sequence contains a glycine
residue at the ®10 position instead of the highly conserved
alanine residue present in all other propeptides. Chu et al. [26]
have shown that an Ala"!!Thr mutation in the propeptide of
human coagulationFactor IX leads to a 30-fold-decreased affinity
of the protein precursor for VKC in itro, and hence to a strongly
increased sensitivity for warfarin in io. Using substrates derived
from ProIX-59 Q}S it was shown that an Ala−"!!Gly mutation
in the propeptide induced a similar effect in itro. Furthermore,
Stanley et al. [10] demonstrated in experiments in itro that the
reduced affinity of the propeptide of OC is due to the glycine at
®10 and valine at ®6. These data may explain why in previous
experiments the propeptide of OC did not seem to play a role in
the binding of d-OC to VKC [12].
In our attempts to characterize the differences between the
binding to VKC of propeptide-containing substrates and of
d-OC we have used inhibitors interacting with either the pro-
peptide-binding site or with the active site on VKC. It was
demonstrated that the carboxylation of propeptide-containing
substrates, such as ProIX-59 Q}S, is inhibited competitively by
ProFIX. Since synthetically prepared d-OC lacks a propeptide and
has no marked sequence similarity in its primary structure with
any of the known propeptides, it seems unlikely that the pro-
peptide-binding site on VKC plays a major role in the binding
of d-OC.
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In agreement with previous data from Azerad et al. [27], we
found that the carboxylation of the short peptide substrate
bEELOMewas inhibited competitively byS-MeTPT. In contrast,
inhibition of both ProIX-59 Q}S and d-OC carboxylation by S-
MeTPT was non-competitive, suggesting that interaction with
the active site is necessary for carboxylation, but does not play a
major role in the high enzyme–substrate affinity. We therefore
postulate the presence of an internal high-affinity binding se-
quence within the mature sequence of d-OC which binds to
neither the propeptide-binding site nor the active site on VKC.
This implies that, besides its active site, VKC contains at least
two distinct sites for binding different types of substrates.
Although no clear function could be attributed to the OC
propeptide, the question remains why this sequence is present
during OC biosynthesis. Speculating about its possible function
we would like to point out that by the binding of covalently
attached propeptides a substantial decrease in the K
m
for vitamin
K hydroquinone is induced [28]. Obviously this decreases the
requirement for vitamin K, the human dietary intake of which
seems to be close to the published recommended daily allowance
values [29]. Also, the substantial under-carboxylation generally
observed in human OC and its strong response to vitamin
K supplementation demonstrates that human daily vitamin K
intake hardly covers the requirement for OC carboxylation [30].
It is possible, therefore, that the propeptide of OC is necessary
for decreasing the K
m
for the VKC cofactor vitamin K hydro-
quinone.Whether this is really the case remains to be investigated.
To establish the high-affinity binding site within d-OC we have
constructed peptides derived from d-OC of various lengths
around its Gla domain. In a purified recombinant human γ-
glutamyl carboxylase system devoid of any endogenous substrate,




values of these d-OC peptides
and proteins. As can be seen in Table 3, both N- and C-terminal
deletion of amino acids flanking the Gla domain results in an
increase of the K
m
values of these peptides. Experiments in which
we compared d-OC"–%* with chimaeric proteins in which the N-
terminus of d-OC was fused with GST showed that recognition
of d-OC by VKC was not influenced by the relatively large GST
(26 kDa). This is important, because in proteins containing the
pro-sequence only the first few N-terminal glutamate residues
(where n ranges from 5–12) are carboxylated. The newly dis-
covered ‘OC-type’ carboxylation-recognition sequence makes
clear that a Gla domain in the centre or at the C-terminus of a
protein is also feasible. Another remarkable point was that the
carboxylation-recognition sequence inOC is formed by sequences
located both at the N-terminal and C-terminal sides of the Gla
motif. This became clear from comparison of the characteristics
of d-OC"–%*, d-OC"–#& and d-OC"&–$*. Since deletion of the last 10
C-terminal residues had no effect, the contribution to VKC
recognition must also be associated with residues 26–39. It is
possible to determine from these results the residues in the N-
and C-terminal parts of the OC molecule that contribute the
most to the high-affinity recognition of VKC.
From the results presented here we can furthermore draw the
conclusion that the EXXXEXC consensus sequence, as postu-
lated by Price et al. [11], does not contribute to the high-affinity
recognition of OC by VKC. The d-OC"$–#& peptide, which consists
of residues 13–25 of d-OC (PDPLEPRREVCEL; the EXXXEXC
part is underlined), has a K
m
value that is three orders of
magnitude higher than those of d-OC"–%* and d-OC"–#&. This is in
agreement with results found by Ratcliffe et al. [31], who used
prothrombin mutants in which glutamic acid residues were
modified to aspartic acid, generating fully carboxylated proteins.
Furthermore, it was shown by several authors using substrates in
itro consisting of a propeptide followed by a random Glu-
containing protein sequence that the EXXXEXC motif is re-
dundant in substrate recognition [9,32,33].
In conclusion, we have demonstrated that the d-OC molecule
binds to VKC in a different way from the other known vitamin
K-dependent proteins. The results of the experiments described
in this paper indicate that VKC recognizes d-OC by two specific
regions flanking the Gla domain, neither of these regions having
structural homology with the propeptide domain. The VKC-
binding domain described here seems specific only for OC, but
might also be present in currently undiscovered vitamin K-
dependent proteins lacking a propeptide motif. These proteins
of as-yet unknown structure and function might be capable of
binding VKC with high affinity in a propeptide-independent
way.
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